Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — Financial Flexibility Index
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Financial Flexibility Index of -1.41x as of March 2026. Free cash flow of $-15.95 Million (operating CF $-16.27 Million minus capex $312.00K) represents -1% of total liabilities ($11.31 Million). Also explore Contineum Therapeutics, Inc. Class A Com equity growth rate to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Contineum Therapeutics, Inc. Class A Common Stock Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for Contineum Therapeutics, Inc. Class A Common Stock across 5 annual periods. Check Contineum Therapeutics, Inc. Class A Com (CTNM) asset resilience to evaluate the company's liquid asset resilience ratio.
Annual Financial Flexibility Index for Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
Year-by-year free cash flow to debt coverage for Contineum Therapeutics, Inc. Class A Common Stock. For the full company profile including market capitalisation, see how much is Contineum Therapeutics, Inc. Class A Com worth.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.52x | $-55.08 Million | $-55.31 Million | $15.65 Million | ▼ -60.9% |
| 2024 | -2.19x | $-32.33 Million | $-32.84 Million | $14.78 Million | ▼ -2295.0% |
| 2023 | 0.10x | $19.76 Million | $19.35 Million | $198.32 Million | ▲ +105.7% |
| 2022 | -1.76x | $-20.00 Million | $-20.12 Million | $11.37 Million | ▲ +39.8% |
| 2021 | -2.92x | $-26.10 Million | $-26.27 Million | $8.93 Million | — |